FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2063574384> ?p ?o ?g. }

• W2063574384 endingPage "439" @default.
• W2063574384 startingPage "433" @default.
• W2063574384 abstract "Abstract Background: We conducted a single‐arm, multicentre phase 2 study to evaluate bortezomib, ascorbic acid and melphalan (BAM) for patients with newly diagnosed multiple myeloma (MM). Methods: Induction consisted of up to eight 28‐d cycles of bortezomib 1.0 mg/m 2 on days 1, 4, 8 and 11, plus oral ascorbic acid 1 g and oral melphalan 0.1 mg/kg on days 1–4, followed by maintenance bortezomib 1.3 mg/m 2 every 2 wk until progression. Results: Among 35 patients enrolled (median age 70 yr), responses occurred in 23/31 evaluable patients (74%) including five (16%) complete, three (10%) very good partial, six (19%) partial and nine (29%) minimal responses. Six patients (19%) had stable disease. Thus, disease control was achieved in 29 (94%) patients. Median times to first and best responses were 2 and 3 months (ranges 1–5 and 1–7), respectively. Median time to progression was 19 months and median overall survival has not been reached (range 2–23+ months). Grade 3 and 4 adverse events occurred in 17 and 5 patients, respectively; the most common were neutropenia, neuropathy and thrombocytopenia. Conclusions: BAM is an efficacious, well‐tolerated and steroid‐ and immunomodulatory drug (IMiD)‐free frontline treatment regimen for MM patients." @default.
• W2063574384 created "2016-06-24" @default.
• W2063574384 creator A5005466085 @default.
• W2063574384 creator A5007526473 @default.
• W2063574384 creator A5021554856 @default.
• W2063574384 creator A5024633335 @default.
• W2063574384 creator A5024701936 @default.
• W2063574384 creator A5040638150 @default.
• W2063574384 creator A5040835019 @default.
• W2063574384 creator A5047556737 @default.
• W2063574384 creator A5048382573 @default.
• W2063574384 creator A5050826635 @default.
• W2063574384 creator A5054313117 @default.
• W2063574384 creator A5064758797 @default.
• W2063574384 date "2009-04-21" @default.
• W2063574384 modified "2023-10-12" @default.
• W2063574384 title "Bortezomib, ascorbic acid and melphalan (BAM) therapy for patients with newly diagnosed multiple myeloma: an effective and well-tolerated frontline regimen" @default.
• W2063574384 cites W1965734230 @default.
• W2063574384 cites W1970734978 @default.
• W2063574384 cites W1978377409 @default.
• W2063574384 cites W1989740966 @default.
• W2063574384 cites W2024123206 @default.
• W2063574384 cites W2049457454 @default.
• W2063574384 cites W2053875306 @default.
• W2063574384 cites W2059733579 @default.
• W2063574384 cites W2073228314 @default.
• W2063574384 cites W2088489718 @default.
• W2063574384 cites W2096207943 @default.
• W2063574384 cites W2102591890 @default.
• W2063574384 cites W2110466835 @default.
• W2063574384 cites W2111650326 @default.
• W2063574384 cites W2117172636 @default.
• W2063574384 cites W2118820477 @default.
• W2063574384 cites W2119584679 @default.
• W2063574384 cites W2120161314 @default.
• W2063574384 cites W2120474651 @default.
• W2063574384 cites W2131915887 @default.
• W2063574384 cites W2148672632 @default.
• W2063574384 cites W2155947749 @default.
• W2063574384 cites W2156748957 @default.
• W2063574384 cites W2556749292 @default.
• W2063574384 cites W2589054503 @default.
• W2063574384 cites W2599425020 @default.
• W2063574384 cites W3145716452 @default.
• W2063574384 cites W4232496617 @default.
• W2063574384 doi "https://doi.org/10.1111/j.1600-0609.2009.01244.x" @default.
• W2063574384 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19226361" @default.
• W2063574384 hasPublicationYear "2009" @default.
• W2063574384 type Work @default.
• W2063574384 sameAs 2063574384 @default.
• W2063574384 citedByCount "22" @default.
• W2063574384 countsByYear W20635743842012 @default.
• W2063574384 countsByYear W20635743842014 @default.
• W2063574384 countsByYear W20635743842015 @default.
• W2063574384 countsByYear W20635743842021 @default.
• W2063574384 countsByYear W20635743842022 @default.
• W2063574384 crossrefType "journal-article" @default.
• W2063574384 hasAuthorship W2063574384A5005466085 @default.
• W2063574384 hasAuthorship W2063574384A5007526473 @default.
• W2063574384 hasAuthorship W2063574384A5021554856 @default.
• W2063574384 hasAuthorship W2063574384A5024633335 @default.
• W2063574384 hasAuthorship W2063574384A5024701936 @default.
• W2063574384 hasAuthorship W2063574384A5040638150 @default.
• W2063574384 hasAuthorship W2063574384A5040835019 @default.
• W2063574384 hasAuthorship W2063574384A5047556737 @default.
• W2063574384 hasAuthorship W2063574384A5048382573 @default.
• W2063574384 hasAuthorship W2063574384A5050826635 @default.
• W2063574384 hasAuthorship W2063574384A5054313117 @default.
• W2063574384 hasAuthorship W2063574384A5064758797 @default.
• W2063574384 hasConcept C126322002 @default.
• W2063574384 hasConcept C141071460 @default.
• W2063574384 hasConcept C185592680 @default.
• W2063574384 hasConcept C197934379 @default.
• W2063574384 hasConcept C2776364478 @default.
• W2063574384 hasConcept C2777063308 @default.
• W2063574384 hasConcept C2777478702 @default.
• W2063574384 hasConcept C2778684742 @default.
• W2063574384 hasConcept C2779609412 @default.
• W2063574384 hasConcept C2781413609 @default.
• W2063574384 hasConcept C29730261 @default.
• W2063574384 hasConcept C2986274086 @default.
• W2063574384 hasConcept C31903555 @default.
• W2063574384 hasConcept C71924100 @default.
• W2063574384 hasConcept C90924648 @default.
• W2063574384 hasConceptScore W2063574384C126322002 @default.
• W2063574384 hasConceptScore W2063574384C141071460 @default.
• W2063574384 hasConceptScore W2063574384C185592680 @default.
• W2063574384 hasConceptScore W2063574384C197934379 @default.
• W2063574384 hasConceptScore W2063574384C2776364478 @default.
• W2063574384 hasConceptScore W2063574384C2777063308 @default.
• W2063574384 hasConceptScore W2063574384C2777478702 @default.
• W2063574384 hasConceptScore W2063574384C2778684742 @default.
• W2063574384 hasConceptScore W2063574384C2779609412 @default.
• W2063574384 hasConceptScore W2063574384C2781413609 @default.
• W2063574384 hasConceptScore W2063574384C29730261 @default.
• W2063574384 hasConceptScore W2063574384C2986274086 @default.
• W2063574384 hasConceptScore W2063574384C31903555 @default.
• W2063574384 hasConceptScore W2063574384C71924100 @default.

• next